Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676724 · ClinicalTrials.gov registry record · Phase 2
Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT04676724 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 108 participants.
The verdict
NCT04676724, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
This study is intended to evaluate if 12 or 24 weeks of treatment with GSK3228836 followed by up to 24 weeks of pegylated interferon (PegIFN) can increase the rate of hepatitis B virus surface antigen (HBsAg) loss in participants on stable nucleos(t)ide analogue (NA) therapy, and whether virologic response can be sustained once PegIFN treatment is discontinued. Participants will be randomized to receive GSK3228836 for 12 or 24 weeks followed by up to 24 weeks of PegIFN.
Interventions
- DRUG GSK3228836
- DRUG PegIFN
- DRUG NA therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2023-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04676724
The ClinicalTrials.gov registry entry for NCT04676724 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GSK3228836 is the first listed.
NCT04676724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04676724 about?
NCT04676724 is a clinical study titled "Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)". This study is intended to evaluate if 12 or 24 weeks of treatment with GSK3228836 followed by up to 24 weeks of pegylated interferon (PegIFN) can increase the rate of hepatitis B virus surface antigen (HBsAg) loss in participants on stable nucleos(t)ide analogue (NA) therapy, and whether virologic r...
What is the current status of trial NCT04676724?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2021-01-28. Estimated completion is 2023-02-17.
What interventions are being tested in trial NCT04676724?
The interventions under investigation include: GSK3228836 (DRUG), PegIFN (DRUG), NA therapy (DRUG).
Who is sponsoring clinical trial NCT04676724?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.